文献速递儿童血液肿瘤与免疫

TPMT、ITPA与NUDT15变异在瑞典儿童急性淋巴细胞白血病巯嘌呤治疗中的作用

The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
PubMed 文献 · J Pediatr · 2019-10-18

该研究回顾性纳入102例接受NOPHO ALL-2000/2008方案治疗的瑞典儿童急性淋巴细胞白血病患者,分析TPMT、ITPA和NUDT15序列变异与6-巯嘌呤(6-MP)敏感性(中性粒细胞减少、发热性中性粒细胞减少及6-MP终剂量)的关系。结果显示TPMT变异与维持II期中性粒细胞减少和发热性中性粒细胞减少风险降低相关,NUDT15变异与6-MP终剂量较低相关,ITPA变异在全治疗期与发热性中性粒细胞减少风险降低相关。

要点

  • ITPA变异与全治疗期发热性中性粒细胞减少风险降低相关,但与6-MP终剂量无关。

核心结论

  • 基于白细胞计数的剂量调整使已知TPMT缺陷患者的中性粒细胞减少和发热性中性粒细胞减少风险降低。
  • NUDT15缺陷患者也进行了剂量调整,表现为6-MP终剂量较低。
  • ITPA缺陷患者在全治疗期分析中发热性中性粒细胞减少风险降低。
  • 数据提示NUDT15在6-MP治疗中起重要作用,结果需在更大队列中确认。

研究设计与样本

  • 回顾性研究纳入102例接受NOPHO ALL-2000和ALL-2008方案治疗的儿童急性淋巴细胞白血病患者。
  • 从医疗记录中收集中性粒细胞减少和发热性中性粒细胞减少事件、TPMT序列变异及6-MP终剂量。
  • 采用焦磷酸测序分析TPMT、ITPA和NUDT15序列变异。

主要发现

  • ITPA变异与中性粒细胞减少、发热性中性粒细胞减少风险增加及6-MP终剂量较低均无关。
  • 全治疗期分析中,ITPA变异与发热性中性粒细胞减少风险降低相关。

临床怎么用

  • 对已知TPMT缺陷患者按白细胞计数调整剂量可降低中性粒细胞减少和发热性中性粒细胞减少风险。
  • 对NUDT15缺陷患者也应进行剂量调整,表现为6-MP终剂量较低。
  • ITPA缺陷可能与全治疗期发热性中性粒细胞减少风险降低相关,但需进一步验证。

局限性

  • 研究为回顾性设计,样本量有限(102例),结果需在更大队列中确认。
  • 未来研究应随访基于白细胞计数的剂量调整是否影响复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the roles of thiopurine methyltransferase (TPMT), inosine triphosphatase (ITPA), and Nudix hydrolase 15 (NUDT15) in 6-mercaptopurine (6-MP) sensitivity during treatment of pediatric patients with acute lymphoblastic leukemia (ALL). STUDY DESIGN: The study included 102 pediatric patients with ALL subject to the Nordic society Of Paediatric Haematology and Oncology (NOPHO) ALL-2000 and ALL-2008 protocols. Episodes of neutropenia and febrile neutropenia, TPMT sequence variants, as well as 6-MP end doses, were collected retrospectively from medical records. TPMT, ITPA, and NUDT15 sequence variants were analyzed using pyrosequencing. RESULTS: TPMT variants were associated with a reduced risk of neutropenia and febrile neutropenia during the maintenance II period (P = .019 and P < .0001, respectively). In addition, a NUDT15 variant was associated with a lower end dose of 6-MP (P = .0097), but not with neutropenia and febrile neutropenia. ITPA variants were not associated with an increased risk of neutropenia, febrile neutropenia, nor lower end dose of 6-MP. However, when analyzing the entire treatment period, ITPA variants were associated with a decreased risk of febrile neutropenia. CONCLUSIONS: White blood cell count-based dose adjustments are regularly performed for known TPMT- deficient patients and results in a reduced risk of neutropenia and febrile neutropenia. Also in NUDT15-deficient patients dose adjustments are performed as indicated by low end dose of 6-MP. ITPA-deficient patients had a decreased risk of febrile neutropenia when analyzing the entire treatment period. Our data suggest that NUDT15 plays an important role in 6-MP treatment and the results should be confirmed in larger cohorts. Future studies should also follow up whether white blood cell count-based dose adjustments affect the risk of relapse.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Wahlund M, Nilsson A, Kahlin AZ, et al. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia. J Pediatr. 2019. PMID: 31635813. doi:10.1016/j.jpeds.2019.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。